IRIS Accounts Production v25.4.0.155 01893173 Board of Directors Board of Directors 1.4.24 31.3.25 31.3.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh018931732024-03-31018931732025-03-31018931732024-04-012025-03-31018931732023-03-31018931732023-04-012024-03-31018931732024-03-3101893173ns15:EnglandWales2024-04-012025-03-3101893173ns14:PoundSterling2024-04-012025-03-3101893173ns10:Director12024-04-012025-03-3101893173ns10:Director22024-04-012025-03-3101893173ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3101893173ns10:SmallEntities2024-04-012025-03-3101893173ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3101893173ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3101893173ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3101893173ns10:FullAccounts2024-04-012025-03-3101893173ns10:CompanySecretary12024-04-012025-03-3101893173ns10:RegisteredOffice2024-04-012025-03-3101893173ns5:CurrentFinancialInstruments2025-03-3101893173ns5:CurrentFinancialInstruments2024-03-3101893173ns5:ShareCapital2025-03-3101893173ns5:ShareCapital2024-03-3101893173ns5:RetainedEarningsAccumulatedLosses2025-03-3101893173ns5:RetainedEarningsAccumulatedLosses2024-03-3101893173ns5:LongLeaseholdAssetsns5:LandBuildings2024-04-012025-03-3101893173ns5:FurnitureFittings2024-04-012025-03-3101893173ns5:LongLeaseholdAssetsns5:LandBuildings2024-03-3101893173ns5:FurnitureFittings2024-03-3101893173ns5:LongLeaseholdAssetsns5:LandBuildings2025-03-3101893173ns5:FurnitureFittings2025-03-3101893173ns5:LongLeaseholdAssetsns5:LandBuildings2024-03-3101893173ns5:FurnitureFittings2024-03-3101893173ns5:CostValuation2024-03-3101893173ns5:AdditionsToInvestments2025-03-3101893173ns5:CostValuation2025-03-3101893173ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3101893173ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3101893173ns5:WithinOneYear2025-03-3101893173ns5:WithinOneYear2024-03-3101893173ns5:BetweenOneFiveYears2025-03-3101893173ns5:BetweenOneFiveYears2024-03-3101893173ns5:AllPeriods2025-03-3101893173ns5:AllPeriods2024-03-31
REGISTERED NUMBER: 01893173 (England and Wales)















ACUMEDIC LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025






ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025










Page

Company information 1

Balance sheet 2

Notes to the financial statements 4


ACUMEDIC LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2025







DIRECTORS: M M Mei
D Mei





SECRETARY: M M Mei





REGISTERED OFFICE: 101-105 Camden High Street
London
NW1 7JN





REGISTERED NUMBER: 01893173 (England and Wales)





ACCOUNTANTS: Venthams Ltd
Phoenix House
Redhill Aerodrome
Kings Mill Lane
Redhill
Surrey
RH1 5JY

ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

BALANCE SHEET
31 MARCH 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 28,560 46,492
Investments 5 7,562 6,278
36,122 52,770

CURRENT ASSETS
Stocks 6 74,202 78,273
Debtors 7 154,165 186,569
Cash at bank 1,528,775 1,471,132
1,757,142 1,735,974
CREDITORS
Amounts falling due within one year 8 793,838 793,980
NET CURRENT ASSETS 963,304 941,994
TOTAL ASSETS LESS CURRENT
LIABILITIES

999,426

994,764

PROVISIONS FOR LIABILITIES 4,562 5,954
NET ASSETS 994,864 988,810

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Retained earnings 993,864 987,810
994,864 988,810

ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

BALANCE SHEET - continued
31 MARCH 2025


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of income and retained earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 November 2025 and were signed on its behalf by:




D Mei - Director



M M Mei - Director


ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025


1. STATUTORY INFORMATION

Acumedic Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
- the company has transferred the significant risks and rewards of ownership to the buyer;
- the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
- the amount of revenue can be measured reliably;
- it is probable that the company will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Long leasehold - Straight line over 11 years
Fixtures and fittings - 10% straight line

Stocks
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11 "Basic Financial Instruments" of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's Balance Sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.


Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the company in independently administered funds.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 51 (2024 - 47 ) .

ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


4. TANGIBLE FIXED ASSETS
Fixtures
Long and
leasehold fittings Totals
£    £    £   
COST
At 1 April 2024
and 31 March 2025 627,768 103,803 731,571
DEPRECIATION
At 1 April 2024 606,391 78,688 685,079
Charge for year 11,927 6,005 17,932
At 31 March 2025 618,318 84,693 703,011
NET BOOK VALUE
At 31 March 2025 9,450 19,110 28,560
At 31 March 2024 21,377 25,115 46,492

5. FIXED ASSET INVESTMENTS
Other
investment
£   
COST
At 1 April 2024 6,278
Additions 1,284
At 31 March 2025 7,562
NET BOOK VALUE
At 31 March 2025 7,562
At 31 March 2024 6,278

6. STOCKS
2025 2024
£    £   
Finished goods 74,202 78,273

ACUMEDIC LIMITED (REGISTERED NUMBER: 01893173)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 1,842 3,863
Amounts owed by group undertakings 121,222 151,821
Other debtors 31,101 30,885
154,165 186,569

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 1,082 3,018
Amounts owed to group undertakings 640,368 553,368
Taxation and social security 126,290 193,011
Other creditors 26,098 44,583
793,838 793,980

9. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2025 2024
£    £   
Within one year 102,600 102,600
Between one and five years 128,250 230,850
230,850 333,450